Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019028234) USE OF GABOXADOL IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/028234 International Application No.: PCT/US2018/044973
Publication Date: 07.02.2019 International Filing Date: 02.08.2018
IPC:
A61K 31/437 (2006.01) ,A61K 9/00 (2006.01) ,A61K 45/06 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
4353
ortho- or peri-condensed with heterocyclic ring systems
437
the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45
Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Applicants:
OVID THERAPEUTICS INC. [US/US]; 1460 Broadway New York, New York 10036, US
Inventors:
DURING, Matthew; US
Agent:
STEEN, Jeffrey S.; US
CARTER, David M.; US
DELUCA, Peter; US
FARRELL, Raymond E.; US
BREW, Michael R.; US
ROSSELLI, Thomas M.; US
Priority Data:
62/541,26004.08.2017US
Title (EN) USE OF GABOXADOL IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS
(FR) UTILISATION DE GABOXADOL DANS LE TRAITEMENT DU DIABÈTE ET D’ÉTATS APPARENTÉS
Abstract:
(EN) Methods and compositions for treating a metabolic disease include administering gaboxadol or a pharmaceutically acceptable salt thereof to a patient diagnosed with a metabolic disease. In embodiments, administering gaboxadol or a pharmaceutically acceptable salt thereof to a patient diagnosed with a metabolic disease is effective to lower one or more of HbA1c level, fasting plasma glucose level, 2-hour oral glucose tolerance test (OGTT) result level, and random plasma glucose level. Gaboxadol or a pharmaceutically acceptable salt thereof may optionally be administered in combination with a hypoglycemic agent.
(FR) L'invention concerne des procédés et des compositions pour le traitement d'une maladie métabolique, qui comprennent l'administration de gaboxadol ou d'un sel pharmaceutiquement acceptable de celui-ci à un patient diagnostiqué avec une maladie métabolique. Dans des modes de réalisation, l'administration de gaboxadol ou d'un sel pharmaceutiquement acceptable de celui-ci à un patient diagnostiqué avec une maladie métabolique est efficace pour abaisser un ou plusieurs niveaux de HbA1c, la glycémie (le taux de glucose dans le plasma) à jeun, le niveau de résultat du test de tolérance orale au glucose (TTOG) en 2 heures, et le taux de glucose dans le plasma aléatoire. Le gaboxadol ou un sel pharmaceutiquement acceptable de celui-ci peut éventuellement être administré en combinaison avec un agent hypoglycémique.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)